ストックスクリーナーアプリを入手
98.37
3.94%
-4.03
アフターアワーズ：
98.37
前日終値:
$102.40
開ける：
$101.75
24時間の取引高:
858.87K
Relative Volume:
0.68
時価総額：
$10.97B
収益：
$2.90B
当期純損益:
$239.11M
株価収益率:
46.59
EPS:
2.1112
ネットキャッシュフロー:
$492.45M
1週間 パフォーマンス:
-5.91%
1か月 パフォーマンス:
+6.58%
6か月 パフォーマンス:
-2.40%
1年 パフォーマンス:
+8.70%
1日の値動き範囲:
$97.59
$101.99
1週間の範囲:
$97.59
$104.64
52週間の値動き範囲:
$81.22
$118.30
Revvity Inc Stock (RVTY) Company Profile
Compare RVTY vs TMO, DHR, IDXX, A, WAT
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
98.37 | 11.42B | 2.90B | 239.11M | 492.45M | 2.1112 |
TMO
Thermo Fisher Scientific Inc
|
472.80 | 179.13B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
184.30 | 132.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.16 | 44.55B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.44 | 39.08B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
365.36 | 36.96B | 3.77B | 449.25M | 240.68M | 7.8556 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-14 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-12-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-12-09 | 開始されました | Goldman | Neutral |
| 2025-10-16 | 開始されました | Guggenheim | Neutral |
| 2025-05-01 | アップグレード | UBS | Neutral → Buy |
| 2025-01-10 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2024-12-13 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-10-15 | アップグレード | Barclays | Equal Weight → Overweight |
| 2024-08-28 | 開始されました | Wells Fargo | Equal Weight |
| 2024-07-08 | 開始されました | Leerink Partners | Outperform |
| 2024-06-03 | 再開されました | Jefferies | Hold |
| 2024-01-16 | ダウングレード | UBS | Buy → Neutral |
| 2024-01-04 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-12-19 | 開始されました | Wells Fargo | Equal Weight |
| 2023-12-13 | 開始されました | Wolfe Research | Peer Perform |
| 2023-09-28 | 開始されました | Bernstein | Outperform |
| 2023-07-19 | 開始されました | Raymond James | Outperform |
| 2023-05-23 | 再開されました | Goldman | Buy |
すべてを表示
Revvity Inc (RVTY) 最新ニュース
(RVTY) Volatility Zones as Tactical Triggers - Stock Traders Daily
Revvity, Inc. Cash Flow – XETR:PKN - TradingView
Revvity, Inc. Balance Sheet – XETR:PKN - TradingView
Stifel cuts Revvity stock price target on softer valuation - Investing.com
Revvity gains on diagnostics strength, faces China headwinds - MSN
Revvity Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Why is Revvity (RVTY) up 2% since last earnings report? - MSN
Why Is Revvity (RVTY) Up 2% Since Last Earnings Report? - Yahoo Finance
What to expect from Revvity's next quarterly earnings report - MSN
RVTY Assumed by Wolfe Research -- Rating Set to Peer Perform - GuruFocus
Revvity Inc (RVTY) Stock Down 3.9% -- Now Undervalued? GF Score: 74/100 - GuruFocus
Wolfe Research initiates Revvity stock coverage with Peerperform - Investing.com UK
Wolfe Research Initiates Revvity(RVTY.US) With Hold Rating - Moomoo
Wolfe Research initiates Revvity stock coverage with Peerperform By Investing.com - Investing.com Nigeria
Revvity Inc. stock underperforms Monday when compared to competitors - MarketWatch
Why Is S&P 500 Attention on Revvity After Earnings Miss? - Kalkine Media
Research Tools & Consumables Stocks Q1 In Review: Revvity (NYSE:RVTY) Vs Peers - Yahoo Finance
Revvity, Inc. (RVTY) Stock Analysis: A Healthcare Innovator With 8.7% Potential Upside - DirectorsTalk Interviews
RVTY unveils Signals BioDesign for faster molecular cloning & R&D data - MSN
Revvity Inc. stock (US76155R1086): NYSE price holds near 100 USD as technical levels draw focus - AD HOC NEWS
Revvity Inc. stock (US76155R1086): insider activity and recent trading in focus - AD HOC NEWS
Revvity (RVTY) Q1 earnings and revenues top estimates - MSN
Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch
A Look at Revvity Inc (RVTY) After 4.6% Gain -- GF Value $120.39 vs Price $101.22 - GuruFocus
Revvity stock (US76155R1086): New share repurchase plan sets tone after recent earnings - AD HOC NEWS
Price-Driven Insight from (RVTY) for Rule-Based Strategy - Stock Traders Daily
RVTY Stock Price and Chart — NYSE:RVTY - TradingView
Revvity stock (US76155R1086): life-science player after recent earnings in focus - AD HOC NEWS
Revvity, Inc. (RVTY) Stock Analysis: A Blend of Healthcare Innovation and Notable Growth Potential - DirectorsTalk Interviews
Revvity, Inc. Trade Ideas — XETR:PKN - TradingView
Revvity stock: Analyst estimates & ratings - MSN
Revvity stock (US76155R1086): cancer test launch and steady demand keep diagnostics group in focus - AD HOC NEWS
Revvity declares $0.07 dividend - MSN
Revvity Stock: Analyst Estimates & Ratings - Barchart.com
Revvity stock (US76155R1086): diagnostics specialist in focus after latest earnings and life-science - AD HOC NEWS
Revvity Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Revvity Inc. stock (US76155R1086): investors weigh latest earnings and diagnostics focus - AD HOC NEWS
There May Be Some Bright Spots In Revvity's (NYSE:RVTY) Earnings - 富途牛牛
Revvity's (NYSE:RVTY) Conservative Accounting Might Explain Soft Earnings - Yahoo Finance
Revvity stock (US76155R1086): Q1 earnings beat and guidance set the tone - AD HOC NEWS
Revvity launches Signals BioDesign to advance biologic research workflows - SelectScience
Revvity (RVTY) Is Down 5.0% After Raising 2026 Outlook And Securing FDA Assay Clearance - Sahm
Revvity stock (US76155R1086): FDA assay clearance, outlook to 2026 and fresh collaboration momentum - AD HOC NEWS
Can Revvity Expand Diagnostics Across the S&P 500 Index? - Kalkine Media
Revvity, Inc. (RVTY): Investor Outlook Reveals 20.94% Potential Upside In Healthcare Innovation - DirectorsTalk Interviews
Revvity stock (US76155R1086): steady diagnostics player after latest quarterly update - AD HOC NEWS
RVTY expands endocrine diagnostics with FDA-cleared testosterone assay - MSN
Revvity stock (US76155R1086): collaboration momentum and diagnostics focus after recent share move - AD HOC NEWS
Revvity Inc (RVTY) 財務データ
収益
当期純利益
現金流量
EPS
2.13%
2.22%
大文字化:
|
ボリューム (24 時間):